ArticleJournal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology2026
Effect of miR-214-3p on Cisplatin Resistance in Oral Squamous Cell Carcinoma by Regulating Ferroptosis Through Targeting GPX4.
Article in Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionEmerging evidence underscores the potential of ferroptosis as a promising therapeutic target in cancer. However, the role of microRNAs (miRNAs) in modulating ferroptosis sensitivity remains largely unexplored, particularly in the context of oral squamous cell carcinoma (OSCC) chemoresistance. This study was designed to investigate the role of miR-214-3p in regulating ferroptosis by targeting glutathione peroxidase 4 (GPX4) and its influence on cisplatin (DDP) resistance in OSCC.
methodsPatients diagnosed with OSCC and receiving DDP-based chemotherapy between February 2022 and February 2024 at our institution were included in this study. Expression levels of miR-214-3p and GPX4 were quantitatively assessed in DDP-sensitive versus DDP-resistant OSCC tissues and cell lines using qRT-PCR and Western blot. Cell viability, IC50 values, and apoptosis were evaluated using the CCK-8 assay and flow cytometry. Intracellular reactive oxygen species (ROS) and Fe
resultsAs an initial assessment of clinical relevance, miR-214-3p was significantly downregulated in DDP-resistant OSCC tissues and cells, whereas GPX4 expression was markedly upregulated. Overexpression of miR-214-3p substantially decreased cell viability, reduced the IC
conclusionOur findings reveal a novel miR-214-3p/GPX4/ferroptosis axis in OSCC DDP resistance. miR-214-3p suppresses GPX4 to promote ferroptosis, thereby reversing DDP resistance. This study identifies miR-214-3p as a potential therapeutic target for overcoming chemoresistance in OSCC by modulating ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.